Disease relevance of Urologic Neoplasms

• Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group [1].
• Two open, nonrandomized studies examined the effect of intensive, high-dose intravenous ibandronate (4 mg on 4 consecutive days, or 6 mg on 3 consecutive days) in patients with breast cancer or other tumor types with opioid-resistant bone pain and in patients with urologic cancer [2].
• Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder [3].
• The association of genetic predisposition to urologic cancers with p53 gene codon 72 polymorphism is not so clear as the previous study of Japanese lung cancer patients, but this polymorphism may play some role in urothelial cancers and renal cell carcinoma, in which smoking is an epidemiological risk factor [4].

High impact information on Urologic Neoplasms

• MSH2 mutation carriers were found to have a significantly higher risk of developing cancer of the urinary tract (P < .05) [5].
• Tissue-specific markers in flow cytometry of urological cancers. II. Cytokeratin and vimentin in renal-cell tumors [6].
• Wave heights for sera from patients with untreated urological cancers significantly exceed those from normal subjects [7].
• In particular, a thorough review of the current literature and recent abstract presentations at scientific meetings was done regarding the potential role of COX-2 in urological cancers (MEDLINE from 1960 to the present, and American Urological Association and American Society of Clinical Oncology annual meeting abstracts from1998 to the present) [8].
• Roughly half of all human malignancies, including many urological cancers, exhibit p53 mutations [9].

Chemical compound and disease context of Urologic Neoplasms

• Conventional and high dose cis-platinum in urological cancer [10].
• Ifosfamide in urologic cancer [11].
• To evaluate the prognostic significance of host immunocompetence in urologic cancer patients, the subsequent clinical course of 95 patients was determined a year after skin testing with dinitrochlorobenzene [12].
• The 4th study of prophylactic intravesical chemotherapy with adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese Urological Cancer Research Group for Adriamycin [13].
• Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract [14].

Biological context of Urologic Neoplasms

• Mutations of tumor suppressor gene p53 have been found in a variety of cancers, including urologic neoplasms [15].

Anatomical context of Urologic Neoplasms

• These results indicate that the adenovirus-mediated expression of a soluble VEGF receptor can be an effective therapy for urological cancer treatment; however, such VEGF-targeted gene therapy is not necessarily accompanied by subsequent antitumor T cell immunity [16].

Gene context of Urologic Neoplasms

• CONCLUSIONS: Currently we are just beginning to understand the molecular mechanisms and clinical effects of COX-2 function and inhibition, and the potential for COX-2 specific inhibitors to affect potentially tumor biology and growth and, thereby, serve as antitumor drugs with therapeutic and chemopreventive roles for urological cancers [8].
• Nevertheless, application of novel therapies to reverse multidrug resistance and to increase efficacy of chemotherapy for urologic cancers should be further pursued, within the setting of controlled clinical trials, to improve on current strategies [17].
• The CEA test in urologic cancer: an evaluation and a review [18].
• Serum beta-2-microglobulin levels in urological cancer [19].
• However, little is known concerning the relationship between DPD expression and clinical malignant potential, especially in urological cancer [20].

Analytical, diagnostic and therapeutic context of Urologic Neoplasms

• At the present time, the CEA test does not reflect the accuracy necessary for an acceptable diagnostic test for the detection of urologic cancer [18].
• OBJECTIVE: To determine the presence of p53 serum antibodies in patients with clinically well-defined urological cancer using a new enzyme-linked immunosorbent assay (ELISA) [21].

References